ReviewCancers2022
A Clinical Guide to Peptide Receptor Radionuclide Therapy with
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 41 citations in OpenAlex.
- Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study.Neuroendocrinology · 2025Trial
- Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment.Molecular pharmaceutics · 2026Article
- Dual-tracer PET/CT and cocktail therapy with [European journal of nuclear medicine and molecular imaging · 2026Article
- Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective.European journal of nuclear medicine and molecular imaging · 2026Review
- A sstR2-targeted radiohybrid theranostic agent for PET imaging and βNpj imaging · 2026Article
- PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).Endocrine-related cancer · 2026Review
- Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.Insights into imaging · 2026Article
- Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients.Current treatment options in oncology · 2026Review
- Neo-adjuvant systemic radiation therapy for inoperable hepatic hilum neuroendocrine tumor withAsia Oceania journal of nuclear medicine & biology · 2026Article
- Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges.Frontiers in pharmacology · 2026Review
- Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.Drug design, development and therapy · 2026Review
- Redefining therapeutic thresholds and global guidelines: Toward precision management of intermediate-sized rectal neuroendocrine tumors.World journal of gastroenterology · 2025Article
- Sequencing Choices and Real-World Clinical Management in Advanced Grade 2/3 GEP-NET Treatment: The Emerging Role of PRRT.Cancers · 2025Review
- The South AustralianESMO gastrointestinal oncology · 2025Article
- The Role of Somatostatin in the Gastrointestinal Tract.Biology · 2025Review
- Comparison of the Hematotoxicity of PRRT with LutatheraCancers · 2025Article
- Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.Journal of neuroendocrinology · 2025Review
- Ac-225 radiochemistry through the lens of [EJNMMI radiopharmacy and chemistry · 2025Article
- Exploring the Chemical Features and Biomedical Relevance of Cell-Penetrating Peptides.International journal of molecular sciences · 2024Review
- Cancer-Targeting Applications of Cell-Penetrating Peptides.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Peptide receptor radionuclide therapy (PRRT) with [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.